Surgical Management of Pancreatic Neoplasms: What’s New?

Current Gastroenterology Reports

Volumn 16, Issue 8, 2014, Pages

  Karachristos, Andreas ^a,b   Esnaola, Nestor F ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Borderline resectable; Intraductal papillary mucinous neoplasms (IPMN); Localized; Locally advanced; Minimally invasive; Neoadjuvant therapy; Pancreatectomy; Pancreatic cancer; Surgery; Surgical margins

Indexed keywords

EID: 84939882295     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0397-x     Document Type: Review

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7.
3. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg. 1984;199:418–25.
4. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatol Off J Int Assoc Pancreatol. 2006;6:17–32.
5. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatol Off J Int Assoc Pancreatol. 2012;12:183–97. A summary of recent international consensus guidelines for the management of IPMNs and mucinous cystic neoplasms of the pancreas.
6. Fritz S, Klauss M, Bergmann F, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg. 2012;256:313–20. A recent retrospective review from the University of Heidelberg which highlights the fact that all "Sendai" negative, BD IPMNS are indeed not benign, and that serum CEA and CA 19–9 may be of value in differentiating benign from malignant BD IPMNs.
7. Wong J, Weber J, Centeno BA, et al. High-grade dysplasia and adenocarcinoma are frequent in side-branch intraductal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2013;17:78–84. discussion p −5.
8. Hirono S, Tani M, Kawai M, et al. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2012;255:517–22.
9. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216:657–65. discussion 65–7. A retrospective review from the Johns Hopkins Medical Institutions which demonstrates that a significant proportion of patients status post complete resection of benign IPMNs will develop new IPMNs (and in some cases, invasive pancreatic cancers) at 1, 5, and 10 years after surgery.
10. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2000;4:567–79.
11. Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg. 2013;257:731–6.
12. Kimbrough CW, St Hill CR, Martin RC, McMasters KM, Scoggins CR. Tumor-positive resection margins reflect an aggressive tumor biology in pancreatic cancer. J Surg Oncol. 2013;107:602–7. A retrospective review from the University of Louisville which suggests that R1 resections are not simply reflections of surgical technique, but also of biological aggressiveness (thus supporting the use of adjuvant multimodal therapy in these patients).
13. NCC clinical practice guidelines in oncology: pancreatic adenocarcinoma, version 1.2014. (Accessed 3/25/14, at http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.) An excellent summary of the evidence supporting current recommendations regarding the work-up, staging, multimodal management, and follow-up of patients with pancreatic adenocarcinoma
14. Kang CM, Chung YE, Park JY, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:509–17.
15. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:68–78. discussion −9. A retrospective series from the University of Texas M.D. Anderson Cancer Center which suggests that neoadjuvant chemoradiation may optimize (retroperitoneal/SMA) margins and decrease local recurrence rates following pancreatectomy for localized pancreatic cancer.
16. Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB Off J Int Hepato Pancreat Biliary Assoc. 2014;16:34–9.
17. Papalezova KT, Tyler DS, Blazer 3rd DG, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106:111–8. A retrospective series from Duke University which suggests that preoperative therapy may allow for better patient selection (and may result in better long-term outcomes) in patients with localized pancreatic cancer.
18. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362–75.
19. Zhao Q, Rashid A, Gong Y, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29–37.
20. Arvold ND, Ryan DP, Niemierko A, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012;118:3026–35.
21. Esnaola NF, Chaudhary UB, O’Brien P, et al. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;88:837–44. A phase II clinical trial from the Medical University of South Carolina which suggests that induction combination chemotherapy, selective chemoradiation, and aggressive surgical resection is well tolerated and results in favorable long-term outcomes in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
22. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749–56.
23. Strobel O, Berens V, Hinz U, et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152:S33–42.
24. Yamamoto Y, Sakamoto Y, Ban D, et al. Is celiac axis resection justified for T4 pancreatic body cancer? Surgery. 2012;151:61–9. This retrospective series from the National Cancer Center Central Hospital in Tokyo highlights the fact that en bloc, celiac axis resection for T4 pancreatic body cancer is associated with high rates of morbidity and poor long-term outcomes, even in highly selected cases performed at a high volume center.
25. Baumgartner JM, Krasinskas A, Daouadi M, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:1152–9.
26. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–47.
27. Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20:964–72.
28. Thomas RM, Truty MJ, Nogueras-Gonzalez GM, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:1696–704.
29. Baker MS, Sherman KL, Stocker S, et al. Defining quality for distal pancreatectomy: does the laparoscopic approach protect patients from poor quality outcomes? J Gastrointest Surg Off J Soc Surg Aliment Tract. 2013;17:273–80.
30. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
31. Jean-Philippe A, Alexandre J, Christophe L, et al. Laparoscopic spleen-preserving distal pancreatectomy: splenic vessel preservation compared with the Warshaw technique. JAMA Surg. 2013;148:246–52.